Go back to the public home page
Hello .
 U.S. 

  • News

    • International News

    • Education

    • Environment

    • Healthcare

    • Technology

      • Internet

    • Science

    • Social and Non-Profit

    • Local News

  • Politics
    and Policy

    • Government

    • Politics

    • Local Government

    • International Policy

  • Business
    and Economy

    • Economy

    • Finance

      • Stock Markets

    • Jobs and Labor

    • Company News

    • Industry News

      • Aerospace

      • Agriculture

      • Chemicals

      • Commodities

      • Construction and Engineering

      • Consumer Electronics

      • Defense

      • Energy

        • Nuclear Energy

        • Oil and Gas

        • Renewable Energy

      • Financial Services

        • Banking

        • Insurance

      • Fishing and Aquaculture

      • Manufacturing

      • Information Technology

      • Metals and Mining

      • Pharmaceuticals and Biotechnology

      • Real Estate

      • Professional and Business Services

        • Legal

      • Telecommunications

      • Tobacco

      • Retail

      • Transportation

        • Air Transportation

        • Maritime Transportation

        • Rail Transportation

        • Road Transportation

      • Utilities

      • Forestry and Wood Industry

  • Arts
    and Culture

    • Art

    • Books and Literature

    • Entertainment

      • Cinema

      • Media

        • Radio and Television

      • Music

  • Lifestyle
    and Leisure

    • Automotive

    • Home and Garden

    • Fashion and Luxury

      • Textile and Apparel

    • Food

    • Travel and Hospitality

    • Boating and Yachting


  • Sports

    • Baseball

    • Basketball

    • Boxing

    • Cricket

    • Cycling

    • Football (American)

    • Football (Australian)

    • Football (Soccer)

    • Golf

    • Hockey

    • Racing

    • Rugby

    • Sailing

    • Skiing and Winter Sports

    • Tennis

    • Volleyball

related announcements

News

  • InterDigital Inc.

    InterDigital Announces Upsize and Pricing of Private Offering of $400[...]

  • City of Dover, DE

    Memorial Day Holiday - Trash & Recycling Collection

  • State of Indiana

    [DCS} My Family, Your Family-Microsoft Teams

More

Education

  • Richard Blumenthal

    Blumenthal Statement on the Shooting at an Elementary School in Uvalde,[...]

  • Maria Cantwell

    Cantwell Statement on the Uvalde, Texas Elementary School Shooting

  • Thomas R. Carper

    Carper Statement on the Uvalde School Shooting

More

Marker Therapeutics Inc.

01/20/2022 | Press release | Distributed by Public on 01/20/2022 05:01

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer - Form 8-K

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.

Sharing and Personal Tools

Please select the service you want to use:

  • Newsvine
  • Digg
  • Delicious
  • StumbleUpon
  • Technorati
  • Buzz
  • Favorites
  • Google Reader

Please use the above public link if you want to share this noodl on another website.

Close

Smartlinks | Marker Therapeutics Inc. | News | Education | Health | Biotechnology | Technology | Biotechnology | Science | Biotechnology | Research | Local News | Business and Economy | Finance | Stock Markets | Security Markets | Stock Markets | Security Markets | Company News | Top Company News | Shareholders | Corporate and Shareholder Meetings | Business Announcement | Products and Services | Corporate Litigation and Regulation | Pharmaceuticals | Lifestyle and Leisure | Leisure | Public Companies | Biotechnology and Medical Research Companies | Börse Frankfurt | Börse Berlin | Börse München | Börse Stuttgart | NYSE American | NYSE ARCA Equities | Turquoise | Nasdaq Global Market | BZX Exchange | BYX Exchange | EDGA Exchange | EDGX Exchange | NYSE National | Nasdaq BX | Nasdaq PSX | FINRA Alternative Display Facility (ADF) | NYSE Chicago

 Back

Copyright ©2006-2022 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact